Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations

²²⁵Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Clemens Kratochwil, Frank Bruchertseifer, Frederik L. Giesel et al. · Journal of Nuclear Medicine · 2016 · 1K citations · Full text

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Kambiz Rahbar, Hojjat Ahmadzadehfar, Clemens Kratochwil et al. · Journal of Nuclear Medicine · 2016 · 812 citations · Full text

Diagnostic Efficacy of ⁶⁸ Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer

Tobias Maurer, Jürgen E. Gschwend, Isabel Rauscher et al. · The Journal of Urology · 2015 · 773 citations

¹⁷⁷Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt et al. · Journal of Nuclear Medicine · 2016 · 518 citations · Full text